PCI Biotech 3rd Quarter report
Lysaker, 17th November 2015 - Please find attached the third quarter 2015 report for PCI Biotech Holding ASA.
Highlights include:
Research collaboration with a top-10 large pharma company initiated
The bile duct study has moved into the fourth dose cohort
Research collaboration with RXi progressing according to plan
Scientific Advisory Committee established
Exploring options for clinical validation of immunotherapy results
PCI Biotech moving to Oslo Cancer Cluster Innovation Park
CEO Per Walday comments: ”We were delighted to announce the research agreement with one of the largest pharma companies in the world. We believe that the PCI technology has the potential to play a role in the realisation of several new therapeutic modalities, including cancer immunotherapy and mRNA therapeutics. This agreement shows that external companies share this view. The collaborative research has been initiated.
We are also pleased to announce the progress in our bile duct study, with the potential to progress into Phase II in first half of 2016.
Our network of internationally renowned experts in the recently established scientific advisory committee has provided valuable input to the assessment of our development opportunities. We are now exploring options for clinical validation of the promising immunotherapy results, as part of the strategy going forward.”
About PCI Biotech
PCI Biotech is a cancer focused biopharmaceutical company headquartered in Norway and listed on the Oslo Stock Exchange (Axess). The company is developing therapeutic products based on its proprietary photochemical internalization (PCI) technology. Originating from world leading research at the Norwegian Radium Hospital, the PCI technology works by inducing triggered endosomal release and may be used to unlock the true potential of a wide array of therapeutic modalities, such as small molecules, vaccines and nucleic acids.
The company currently has a bile duct cancer program in phase I/II clinical development. Bile duct cancer is an orphan indication without any approved medicinal products and a high medical need for better local treatments. It is an indication well suited for PCI treatment, with easy light access for intraluminal surface illumination through routine endoscopic methods and an active generic drug (gemcitabine) significantly enhanced by PCI.
The company is also developing PCI as a CTL (Cytotoxic T Lymphocyte) induction technology for therapeutic and prophylactic vaccination. It has been demonstrated both in vivo and ex vivo that PCI significantly increases the number of activated antigen-specific CTLs by enhancing the MHC I antigen presentation of antigen presenting cells. When applied in the emerging field of cancer immunotherapy, PCI can be used to enhance the important cytotoxic effect of therapeutic cancer vaccines.
PCI Biotech follows a strategy to create value by improving the effect both of existing cancer drugs and by realizing the large potential in new therapeutics, including therapeutic vaccines.
Contact information:
PCI Biotech Holding ASA, Strandveien 55, N-1366 Lysaker
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429